JHLT Open最新文献

{"title":"Induction therapy confers survival advantage in mechanically supported patients regardless of peak CPRA in heart transplantation","authors":"Nataliya Bahatyrevich MD, MS ,&nbsp;Reid Dale PhD ,&nbsp;Matthew Leipzig BSc ,&nbsp;Katharine Casselman Pines MPH ,&nbsp;Shirin Jimenez MD ,&nbsp;Maria Currie MD, PhD","doi":"10.1016/j.jhlto.2025.100246","DOIUrl":"10.1016/j.jhlto.2025.100246","url":null,"abstract":"<div><h3>Background</h3><div>There is no consensus regarding induction therapy in patients on mechanically circulatory support (MCS) listed for heart transplantation. We sought to elucidate differences in outcomes between no induction and induction.</div></div><div><h3>Methods</h3><div>A total of 3,987 patients were analyzed from the UNOS database from January 2018 through December 2022. Patients on Extracorporeal Membrane Oxygenation (ECMO), HeartMate 3, Impella 5.0 or 5.5, and intra-aortic balloon pump (IABP) and receiving no induction, anti-IL2R antibodies, or T cell depleting agent (TCDA) were included.</div></div><div><h3>Results</h3><div>Of 3,987 patients, 1,288 (32.3%) received no induction, 1,566 (39.3%) received anti-IL2R antibodies, and 1,133 (28.4%) received TCDA. A total of 1,895 (47.5%) were supported with IABP; 1,098 (27.5%) with HeartMate 3; 489 (12.3%) with Impella 5.0 or 5.5; 351 (8.8%) with ECMO; and 154 (3.9%) with combination of the above devices. Comparison of 1-year survival between no induction, anti-IL2R, and TCDA groups in all MCS patients revealed significantly worse survival among those receiving no induction (p&lt;0.0001). Subgroup analysis of peak CPRA 0% patients revealed that no induction had significantly worse survival at 1 year (p=0.002). Analysis of acute rejection at 1 year showed a significantly decreased number of rejection episodes in the TCDA group compared to no induction (OR 0.65, CI 0.47-0.88, p=0.006).</div></div><div><h3>Conclusions</h3><div>Patients requiring MCS prior to heart transplantation have significantly improved post-transplant survival with induction therapy, regardless of their peak CPRA. TCDA confers decreased number of acute rejection episodes at 1 year in this patient population.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100246"},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-guided biopsy in heterotopic heart transplant: A case report","authors":"Isaac Tea MD ,&nbsp;Stephanie Fuentes Rojas MD ,&nbsp;Varshni Nandakumar BS ,&nbsp;Su-Min Chang MD ,&nbsp;Ponraj Chinnadurai MBBS, MMST ,&nbsp;James Young MD ,&nbsp;Alan Lumsden MD ,&nbsp;Arvind Bhimaraj MD, MPH","doi":"10.1016/j.jhlto.2025.100259","DOIUrl":"10.1016/j.jhlto.2025.100259","url":null,"abstract":"<div><h3>Background</h3><div>Heterotopic heart transplantation is a surgical technique that has not been embraced broadly. In this historic technique, the donor heart is sutured in parallel to the recipient heart with both hearts in place.</div></div><div><h3>Case summary</h3><div>We report a patient who received a heterotopic heart transplant at our institution more than 15 years ago with preserved cardiac function and who needed a myocardial biopsy due to heart failure symptoms. Due to complex anatomy, a cardiac computed tomography imaging reconstruction was used to create a live roadmap overlay on fluoroscopy during myocardial biopsy. Such a technique facilitated obtaining a biopsy successfully and safely to rule out rejection.</div></div><div><h3>Discussion</h3><div>Heterotopic heart transplantation is a surgical procedure that has a potential physiologic and immunologic advantage in select patients needing a heart transplant. Utilizing imaging guidance for navigating complex anatomy to perform a myocardial biopsy can have potential applications in providing safe and increasing yield in patchy diseases of the heart.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100259"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The approach to placement of a continuous-flow intracorporeal ventricular assist device in small left ventricle","authors":"Ryaan EL-Andari MD ,&nbsp;Josiane Dion MD ,&nbsp;Jennifer Conway MD, MSc ,&nbsp;Tara Pidborochynski MSc ,&nbsp;Lindsey Carter MD ,&nbsp;Gurmeet Singh MD, MSc ,&nbsp;Roderick MacArthur MD, MSc ,&nbsp;Steven Meyer MD, PhD ,&nbsp;Devilliers Jonker MD ,&nbsp;Darren H. Freed MD, PhD ,&nbsp;Holger Buchholz MD","doi":"10.1016/j.jhlto.2025.100256","DOIUrl":"10.1016/j.jhlto.2025.100256","url":null,"abstract":"<div><h3>Background</h3><div>The HeartMate 3 (HM3) has become among the most widely utilized durable left ventricular (LV) assist devices (LVAD) owing to reduced rates of pump thrombosis, bleeding, and stroke. One limitation of the HM3 is its large size, which poses a challenge for implantation in smaller LVs. Herein, we describe a novel technique for durable LVAD implantation in patients with a small LV.</div></div><div><h3>Methods</h3><div>Patients who underwent durable LVAD implantation from January 2020 to August 2024 were included in this study. The modified technique involved excision of the mitral valve (MV) and associated apparatus to create room for the LVAD inflow. The primary outcome was mortality, and secondary outcomes included rates of postoperative complications and hemodynamic parameters. Patient follow-up was until September 2024.</div></div><div><h3>Results</h3><div>Eleven patients were included in this study. All patients received an HM3. The median preoperative LV end-diastolic diameter was 5.1 cm. The median total time on LVAD was 149 days, and overall mortality was 27.2% occurring a median of 204 days post-LVAD implantation. Four patients (36.4%) underwent heart transplantation and 4 (36.4%) were alive on LVAD at last follow-up. Proportions of morbidity included readmission for heart failure (<em>n</em> = 2, 18.2%), cerebrovascular accident (<em>n</em> = 2, 18.2%), and pump thrombosis (<em>n</em> = 0).</div></div><div><h3>Conclusions</h3><div>The small LV has been a significant challenge for durable LVAD insertion and is often considered a contraindication. A modified approach to LVAD insertion, including excision of the MV and associated apparatus and alignment of the LVAD inflow cannula with the MV orifice, allows for LVAD implantation in patients with a small LV.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100256"},"PeriodicalIF":0.0,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation","authors":"Lisa M. Raven MBBS, FRACP ,&nbsp;Jerry R. Greenfield MBBS (Hons 1), PhD, FRACP ,&nbsp;Andrew Jabbour BSc (Med), MBBS (Hons), PhD, FRACP ,&nbsp;Peter S. Macdonald MBBS, MD, PhD, FRACP ,&nbsp;Christopher A. Muir MBBS (Hons), FRACP, PhD","doi":"10.1016/j.jhlto.2025.100255","DOIUrl":"10.1016/j.jhlto.2025.100255","url":null,"abstract":"<div><div>Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m² (interquartile range [IQR] −13 to +11)), compared to a change of −15 ml/min/1.73 m² (IQR −27 to +1) in patients not exposed to SGLT2i (<em>p</em> = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, <em>p</em> = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100255"},"PeriodicalIF":0.0,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic mesenchymal stromal cell therapy on primary graft dysfunction after lung transplantation","authors":"Abbas Ali Qayyum MD, MSc, PhD ,&nbsp;Thomas Kromann Lund MD, PhD ,&nbsp;Pia Bredahl Jensen MD ,&nbsp;Kristine Jensen MD ,&nbsp;Mandana Haack-Sørensen MSc, PhD ,&nbsp;Annette Ekblond MSc, PhD ,&nbsp;Morten Juhl Nørgaard MSc, PhD ,&nbsp;Hasse Møller-Sørensen MD, PhD ,&nbsp;Anders Bruun Mathiasen MD, PhD ,&nbsp;Christian Holdflod Møller MD, PhD ,&nbsp;Sara Bird Rørvig MD ,&nbsp;Anna Kalhauge MD ,&nbsp;Helle Bruunsgaard MD, PhD, DMSc ,&nbsp;Thomas Litman MSc ,&nbsp;Ellen Mønsted Johansen MSc ,&nbsp;Lisbeth Drozd Højgaard MSc, PhD ,&nbsp;Jens Kastrup MD, DMSc ,&nbsp;Michael Perch MD","doi":"10.1016/j.jhlto.2025.100254","DOIUrl":"10.1016/j.jhlto.2025.100254","url":null,"abstract":"<div><h3>Background</h3><div>Primary graft dysfunction (PGD) is common in lung transplantation affecting 15–30% of recipients. It represents a multifactorial injury to the transplanted lung within the first 72 hours after transplantation.</div><div>We aimed to investigate clinical safety and efficacy of allogeneic adipose tissue-derived stromal cells (ASCs), as an add-on therapy in patients undergoing double lung transplantation.</div></div><div><h3>Methods</h3><div>Single center, double-blinded, investigator-initiated randomized phase I/II study with intravenous infusion of either ASCs or placebo within two hours after lung transplantation. A total of 31 patients were included and randomized 1:1:1 to either 200 million or 100 million ASCs, or placebo infusion.</div><div>The primary endpoint was difference in PGD grade 72 hours after transplantation between groups.</div></div><div><h3>Results</h3><div>No significant differences in PGD were seen between the 3 groups 72 hours after lung transplantation (P=0.426). Combined ASC groups compared to placebo group did not show any difference in PGD 72 hours after transplantation (P=0.252). A reduced progression in PGD from day 1 to day 3 and day 2 to day 3 was observed between the ASC treated patients and patients in the placebo group (P=0.034 and P=0.034, respectively). There were no significant differences in number of serious adverse events or in secondary endpoints such as kidney function, lung function, or quality-of-life between groups.</div></div><div><h3>Conclusions</h3><div>Intravenous infusion of allogeneic ASCs in patients immediately after double lung transplantation was safe. The therapy did not show statistic difference in PGD between groups 72 hours after lung transplantation.</div></div><div><h3>Clinical trial registration information</h3><div>EudraCT number 2019–004848-30 and NCT04714801.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100254"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Transplant Outcomes by Surgeon Practice and Volume","authors":"Jessica M. Ruck MD PhD ,&nbsp;Shi Nan Feng BSPH ,&nbsp;Mary G. Bowring MPH ,&nbsp;Alice L. Zhou MS ,&nbsp;Jinny S. Ha MD MHS ,&nbsp;Antonio Polanco MD ,&nbsp;Christian A. Merlo MD MPH ,&nbsp;Errol L. Bush MD","doi":"10.1016/j.jhlto.2025.100237","DOIUrl":"10.1016/j.jhlto.2025.100237","url":null,"abstract":"<div><h3>Objective</h3><div>Lung transplants (LT) are performed by surgeons whose practice may include only lung transplants (LT) or lung and heart transplants (L&amp;HT). We examined whether LT outcomes differed by surgeon practice and volume.</div></div><div><h3>Methods</h3><div>We identified all LT in adult U.S. recipients 05/2007-06/2022 using OPTN. We classified surgeons by practice (LT vs. L&amp;HT) and transplant volume (2-20, 21-40, 41-60, or &gt;60) and compared post-transplant morbidity and mortality using multivariable regression adjusted for donor, recipient, and transplant characteristics.</div></div><div><h3>Results</h3><div>Of 635 surgeons, 331 (51.1%) were LT and 304 (47.9%) were L&amp;HT surgeons. They performed 30,223 transplants, including 9,807 (32.5%) by LT and 20,416 (67.5%) by L&amp;HT surgeons. Recipients of transplants by L&amp;HT vs. LT surgeons were less likely to receive post-transplant ECMO (7.9% vs. 8.5%; aOR 0.86, 0.76-0.97, p=0.02) but had similar odds of prolonged ventilation (31.3% vs. 31.5%; aOR 1.01, 95% CI 0.94-1.08, p=0.87), reintubation (18.6% vs. 18.3%; aOR 1.04, 0.98-1.11, p=0.20), airway dehiscence (1.5% vs. 1.6%; aOR 1.01., 0.82-1.23, p=0.94), and 1-year rejection (24.1% vs. 23.0%; aOR 1.04, 0.98-1.12, p=0.20), and they had 4% higher risk of 10-year mortality (70.0% vs. 67.6%; aHR 1.04, 95% CI 1.00-1.08, p=0.046). Additionally, performing &gt;60 lung transplants over the study period was associated with 7% lower 5-year mortality compared to performing only 2-20 transplants (aHR 0.93, 95% CI 0.88-0.98, p=0.004).</div></div><div><h3>Conclusions</h3><div>Surgeons’ practice patterns and lung transplant volume were significantly associated with post-transplant mortality, indicating the importance of experience in achieving optimal outcomes for a technically difficult procedure such as a lung transplant.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100237"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of lung transplantation from SARS-CoV-2 positive donors during the Omicron wave","authors":"Sonya M. Kothadia ,&nbsp;Cameron R. Wolfe ,&nbsp;Arthur W. Baker ,&nbsp;Katherine A. Young ,&nbsp;John M. Reynolds ,&nbsp;Matthew G. Hartwig ,&nbsp;Amanda Rooney ,&nbsp;Madeleine R. Heldman","doi":"10.1016/j.jhlto.2025.100249","DOIUrl":"10.1016/j.jhlto.2025.100249","url":null,"abstract":"<div><div>Early observations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission via lung transplantation have led to frequent discard of lungs from donors with positive SARS-CoV-2 tests. We compared survival between lung transplant recipients (LUTRs) with SARS-CoV-2 (+) (<em>n</em> = 11) and SARS-CoV-2 (-) donors (<em>n</em> = 192) transplanted from January 30, 2022 to March 31, 2024. Three of the 11 SARS-CoV-2 (+) donors had positive lower respiratory tract (LRT) tests. Two of their 3 recipients developed post-transplant SARS-CoV-2 infections, including one LUTR who died 11 days post-transplant. LUTRs with SARS-CoV-2 (+) donors had higher 30-day mortality (2/11 [18.2%] vs 7/192 [3.6%], <em>p</em> = 0.02), but there was no significant difference in 1-year mortality (2/11 [18.2%] vs 27/192 [14.1%], <em>p</em> = 0.56). Only 3 (27%) LUTRs with SARS-CoV-2 (+) donors developed acute cellular rejection in the first post-transplant year, and none were diagnosed with chronic lung allograft dysfunction. These findings support consideration of SARS-CoV-2 (+) lung donors, especially when LRT testing is negative.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100249"},"PeriodicalIF":0.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial disparities in lung function by pulmonary function testing among lung transplant candidates and race-specific reference equations","authors":"Daniel M. Guidot MD MPH ,&nbsp;Mackenzie Wood MB ,&nbsp;Emily Poehlein MB ,&nbsp;Scott Palmer MD MHS ,&nbsp;Lisa McElroy MD MS FACS","doi":"10.1016/j.jhlto.2025.100252","DOIUrl":"10.1016/j.jhlto.2025.100252","url":null,"abstract":"<div><div>Non-White patients with interstitial lung disease (ILD) experience racial disparities in lung transplant waitlist mortality. Race-specific equations for spirometry may contribute by underestimating restriction severity in non-White candidates. We analyzed US lung transplant candidates to assess for disparities in forced vital capacity (FVC) at listing, comparing absolute and adjusted values using race-specific and race-neutral equations. We identified 17,457 adults with ILD listed May 4, 2005 to September 31, 2023. At listing, mean absolute FVC was higher for White patients (2.03 ± 0.80<!--> <!-->liters) than Black patients (1.61 ± 0.67<!--> <!-->liters) and Asian patients (1.49 ± 0.86<!--> <!-->liters). Differences were attenuated after applying race-specific equations (White patients 50.0 ± 17.5%, Black patients 47.7 ± 17.9%, Asian patients 46.2 ± 24.2%). Compared with race-neutral equations, race-specific equations had higher odds of classifying FVC as severe (≤40%) requiring listing in White patients (OR 1.37, 95% CI 1.28–1.40) but lower odds in Black patients (OR 0.82, 95% CI 0.74–0.90). Using race-neutral equations might help improve racial disparities for lung transplant candidates with ILD.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chest wall strapping in a porcine model: A model for the physiology of the oversized lung allograft","authors":"Eric Abston ,&nbsp;Michael Eberlein","doi":"10.1016/j.jhlto.2025.100248","DOIUrl":"10.1016/j.jhlto.2025.100248","url":null,"abstract":"<div><div>Restrictive lung disease (RLD) is the leading indication for lung transplantation. Donor-to-recipient size matching is challenging in RLD, especially oversizing. Chest-Wall-Strapping (CWS) is a technique forcing the lung to operate at lower volumes. We developed a porcine model of CWS to investigate limits of oversizing. Farm-raised pigs were intubated and mechanically ventilated. Computer tomography (CT) volumetry demonstrated that Total Lung Volume (TLV) at 25<!--> <!-->cm<!--> <!-->H₂O end-expiratory pressure was 1,204 ml at baseline. Application of increasing doses of CWS reduced TLV to 879 ml (CWS-cuff inflated to 35 mm<!--> <!-->Hg) and reduced TLV to 620 ml (CWS-cuff inflated to 50 mm<!--> <!-->Hg). At 50 mm<!--> <!-->Hg of CWS (50% TLV reduction) atelectasis of the lung bases was evident. Lung elastance was increased with CWS. CT lung-density at 35 mm<!--> <!-->Hg CWS (30% reduction in TLV) was normal for the inflation state of the lung. Physiological limits of oversizing should be considered for optimal lung function.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100248"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nightmare case of repeated hemorrhagic pancreatitis due to pancreatic head cancer in the acute stage after two-stage lung transplantation","authors":"Tatsuya Hayashi ,&nbsp;Shin Tanaka ,&nbsp;Tsuyoshi Ryuko ,&nbsp;Yasuaki Tomioka ,&nbsp;Kentaroh Miyoshi ,&nbsp;Mikio Okazaki ,&nbsp;Seiichiro Sugimoto ,&nbsp;Shinichi Toyooka","doi":"10.1016/j.jhlto.2025.100245","DOIUrl":"10.1016/j.jhlto.2025.100245","url":null,"abstract":"<div><div>In Japan, due to the shortage of deceased organ donors, the use of two-stage lung transplantation (LTx), specifically sequential single-lung transplants (SSLTs), has been increasing. This approach starts immunosuppressive therapy after the first transplantation, which increases the risk of malignancies. Here, we present a case of fatal perioperative hemorrhagic pancreatitis caused by pancreatic head cancer following SSLTs. This case highlights significant challenges in diagnosis and treatment.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100245"},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}